Entera Bio's Formulated Human Parathyroid Hormone Shows Encouraging BMD Data

Entera Bio Ltd ENTX has presented the 6-month bone mineral density (BMD) data from its Phase 2 trial of EB613, an oral formulation of human parathyroid hormone (PTH), for osteoporosis.
The Phase 2 Dose-Ranging study showed clinically significant changes in increases in BMD at the spine, femoral neck, and total hip.
Patients receiving 2.5 mg oral PTH had a placebo-adjusted increase of 3.78% in the lumbar spine (LS) BMD.
Additionally, there was a highly statistically significant dose-dependent increase in LS BMD across all dose groups.
Pooled 2.5 mg EB613 group had a significant placebo-adjusted 2.76% increase in the femoral neck and a 1.84% increase in total hip BMD.
Significant decrease in serum CTX (of 21% from baseline at 6 months while P1NP was unchanged.
The safety profile of EB613 was consistent with and similar to the known profile of injectable PTH (Forteo).
Price Action: ENTX stock is down 1.97% at $4.49 during the market session on the last check Wednesday.